Blogs, Articles & News
AI for prostate MRI classification has evolved rapidly, but data privacy, limited annotations, and domain variability still slow its translation
As artificial intelligence becomes central to prostate MRI interpretation, one fundamental question remains: can clinicians truly trust what they don’t
Artificial intelligence in prostate MRI is only as strong as the data it learns from. An AI model can learn
Despite major advances in artificial intelligence for prostate MRI, several real-world challenges remain. From subtle, low-contrast lesions and patient motion
As artificial intelligence continues to transform prostate MRI analysis, its success in everyday clinical practice hinges on more than just
AI-based prostate MRI lesion classification delivers tremendous diagnostic power, but its true impact depends on seamless integration into clinical workflows
The field of medical imaging is in a constant state of evolution, and nowhere is this more apparent than in
MRI-based prostate cancer lesion classification has moved beyond simple image interpretation. Today, it directly influences how physicians make critical diagnostic
Artificial intelligence in prostate MRI has made enormous strides. Research has shown that AI can identify, segment, and classify suspicious
Comparing artificial intelligence (AI) models across different studies is essential to understanding progress in prostate MRI lesion classification. Despite an
Developing artificial intelligence for prostate MRI isn’t just about training a model that performs well on paper. An algorithm can
When evaluating artificial intelligence for prostate MRI analysis, it’s tempting to ask for a single, simple “accuracy” score. However, in
Artificial intelligence (AI) in prostate MRI is transforming how we detect and diagnose cancer. However, one of the biggest challenges
Combining MRI-derived radiomic features with clinical data like PSA levels, biopsy results, and patient demographics is advancing prostate cancer lesion
Deep learning has transformed prostate MRI analysis by automating lesion detection, segmentation, and classification. These AI models, built on Convolutional
While deep learning architectures like neural networks dominate today’s AI headlines, classical machine learning (ML) algorithms remain highly relevant and
For radiomics to become a truly useful tool in clinical practice, its features must be consistent and comparable across different
In medical imaging, particularly for prostate MRI, how we teach a computer to “see” is everything. The goal is to
Radiomics is a powerful field that converts medical images, like a prostate MRI, into a vast amount of quantitative data.
Radiomics is the process of converting medical images, such as MRIs, into a vast amount of high-dimensional, quantitative data. This
Prostate MRI is a powerful diagnostic tool, offering a detailed view inside the body to help physicians find and assess
Multi-parametric MRI (mpMRI) has become a cornerstone in the modern diagnosis and management of prostate cancer. By combining anatomical and
Dynamic Contrast-Enhanced MRI (DCE-MRI) is a powerful imaging sequence that adds a functional dimension to prostate cancer diagnosis. While T2-weighted
Magnetic Resonance Imaging (MRI) has transformed our ability to see inside the human body without invasive procedures. For prostate cancer,
Prostate cancer is one of the most common cancers affecting men, but early detection dramatically improves outcomes. For decades, clinicians
Can Young Men Get Prostate Cancer? Understanding the Facts Prostate cancer is often seen as a disease of older men,
Prostate cancer diagnosis is getting smarter, faster, and more precise. That’s the promise of AI and prostate cancer research coming
Expanding the Role of Deep Learning in Cancer Detection Deep learning, a powerful subset of artificial intelligence (AI), has fundamentally
Advancements in artificial intelligence (AI) are revolutionizing the field of cancer research, and Bot Image stands at the forefront of
Prostate cancer is one of the most common forms of cancer in men, and early detection is critical to improving
Understanding how doctors determine the stage and aggressiveness of prostate cancer is crucial for patients and their loved ones. This
Introduction Prostate cancer is a significant health concern for many men worldwide. It is the second most common cancer among
Prostate cancer is one of the most common cancers affecting men worldwide. Early detection plays a crucial role in managing
Introduction Prostate cancer is a significant health concern for men worldwide. Early detection is crucial for successful treatment and better
Prostate cancer is one of the most common cancers among men worldwide, making early detection vital for effective treatment. Understanding
Unveiling the Silent Threat Prostate cancer is a topic that many shy away from, yet understanding its early warning signs
Prostate cancer is one of the most common cancers affecting men worldwide. However, despite its prevalence, there is still considerable
Introduction Prostate cancer is a significant concern for men, especially as they age. Early detection is crucial for effective treatment
Randall W. Jones, D.Eng. (PhD, MBA) EARLY DETECTION through Screening Population-Based Screening Studies Screening for Prostate Cancer (PCa) continues to
Overview: ProstatIDTM is North America’s first FDA-Cleared Prostate Cancer SCREENING, Detection and Diagnostic AI software. With 94% AUROC (Area under
TeraRecon, on March 18, 2023 CAMBRIDGE, Mass., Mar. 18,2023 /PRNewswire/ — The Eureka Clinical AI platform, from ConcertAI’s TeraRecon, now
FOR IMMEDIATE RELEASE Bot Image, an Omaha-based MRI medical device company has developed an AI-driven medical device CAD software to…
Just released, The Healthcare Disruptor, by Dr. Randall W Jones. Dr. Jones writes about his journey from rural cowboy to medical device expert and CEO challenging the healthcare system with his inventions…
Bot Image Inc: Facilitating Early Detection through Disruptive Technology In undetermined and unsettled times, one must be open to…
DR. RANDALL W. JONES FOUNDER & CEO OF BOT IMAGE, INC From joining the military at a young age to excelling at civilian jobs to…
Bot Image, Inc., a Nebraska and Maine based Artificial Intelligence medical device company, has received FDA-clearance on its ProstatIDTM AI
ProstatID, THE AI software FDA-cleared for not only detection and diagnosis of PCa, but also for screening using bpMRI. Yes,
Bot Image, Inc., a Nebraska and Maine based Artificial Intelligence medical device company (www.botimageai.com), raised the performance bar with its
AI medical device company Bot Image is highlighting the performance of its ProstatID in a study evaluating its ability to detect, diagnose, and screen for prostate cancer.
Dr. Randall Jones, CEO of BotImage and two other AI companies chosen to participate with GE HealthCare presenting during GE’s Innovation
Dr. Randall Jones is one of the speakers this year. Come visit the GE Healthcare Booth #7324 on Nov. 30th at 1:35pm CT.
A prostate cancer diagnosis can be devastating news for the one in seven men who develop the disease in their lifetimes. Annually, 30,000…
We recently sat down with our founder to ask 10 questions about the company, the industry, and what are the options men have when facing…
We recently sat down with our CEO in his library to discuss the mission, vision, and values of Bot Image. We discussed ProstatID and the…
We’re proud to announce that in partnership with our beta testing site, we processed our first test case using the cloud-based architecture on 6/18/2020.
The Bot Image team has been hard at work trying to obtain FDA clearance. We’re excited to announce that we have passed the first major milestone on July 21, 2020.
Trial Site News features the latest coverage of clinical research. Read the article here: